Most launch forecasts tell the same story:
- Early traction
- Accelerating adoption
- Compounding growth
The problem is that story breaks far more often than leaders expect.
Despite strong science, regulatory approval, and real product innovation, most launches fail to meet their projected trajectory.
Not because the product isn’t good, but because the market never felt compelled to change.
That’s the pattern at the center of the Commercial Growth Framework.
It shows why projected acceleration rarely materializes—and why growth does not improve just because time passes.
Your forecast assumes momentum.
What it doesn’t account for is the inertia blocking market belief.
And inertia does not fade with time.
It holds—until belief breaks it.
What the Model Actually Assumes:
Most five-year models don’t assume only top line growth.
They assume improving efficiency over time:
- Win rates improve.
- Market penetration accelerates.
- Each deal builds off the last.
That only happens if one condition is true: resistance declines over time.
But resistance doesn’t decline because a company launched a product.
It doesn’t decline because awareness exists.
And it doesn’t decline even when a product is objectively better.
Resistance declines only when the market believes the current way is no longer acceptable. Until that happens, every forecast plan is carrying risk—whether leaders recognize it or not.
Leadership teams engineer things they can measure:
- Clinical validation
- Regulatory readiness
- Manufacturing
- Market access planning
What they don’t engineer is what matters most: Whether the market is willing to change.
If belief hasn’t shifted:
- Every deal must be won independently.
- Resistance resets account by account.
- Growth is unreliable and linear at best.
That’s not scale. That’s effort. And effort doesn’t compound.
The Commercial Growth Framework exposes the missing variable.
The inflection point is where growth either begins to accelerate—or never does.
It occurs only after the market crosses the Market Belief Threshold.
Before that:
- Resistance persists.
- Risk stays elevated.
- Growth remains fragile.
After that:
- Switching feels safer than staying.
- The old standard becomes harder to defend.
- Revenue becomes sustained, not episodic.
The difference isn’t product quality or clinical evidence. It’s whether belief has shifted enough for the market to move.
Corindus developed one of the first robotic-assisted systems for coronary and peripheral interventions. The promise was compelling: remove physicians from radiation exposure while improving procedural precision.
The technology worked. Clinical studies showed significant reductions in radiation exposure. Regulators cleared the system. The company was acquired by Siemens Healthineers for $1.1 billion.
But adoption never got traction.
Procedures took longer than manual approaches. Complex cases often required conversion back to traditional techniques. Hospitals faced higher costs with no clear improvement in outcomes.
Clinicians saw the benefit—but not enough reason to change how they practiced.
In less than four years, Siemens discontinued the cardiovascular robotics program after the expected growth curve never materialized, writing down $362 million.
Growth doesn’t accelerate because a product works. It accelerates when staying the same is no longer acceptable.
In the next Launch Code, we will unpack the inflection point more precisely—what it is, what it’s not, and why most teams do not realize they’ve missed it until forecast risk is already visible.
Reduce commercial launch risk before you GTM.
